Vertex Pharmaceuticals (VRTX) Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $11.7 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 17.2% year-over-year to $11.7 billion in Q1 2026; TTM through Mar 2026 was $11.7 billion, a 17.2% increase from a year earlier, with the FY2025 full-year figure at $11.2 billion, up 16.72% from the prior year.
• Current Assets climbed to $11.7 billion in Q1 2026 per VRTX's latest filing, from $11.2 billion in the prior quarter.
• Across five years, Current Assets topped out at $14.7 billion in Q3 2023 and bottomed at $8.9 billion in Q2 2024.
• The 5-year median for Current Assets is $11.5 billion (2022), against an average of $11.7 billion.
• Across the five-year window, Current Assets surged 38.62% in 2022 and plunged 35.55% in 2024, its largest moves.
• Year by year, Current Assets stood at $13.2 billion in 2022, then grew by 6.87% to $14.1 billion in 2023, then sank by 32.15% to $9.6 billion in 2024, then gained by 16.72% to $11.2 billion in 2025, then gained by 4.73% to $11.7 billion in 2026.
• Per Business Quant, the three latest VRTX Current Assets figures stand at $11.7 billion (Q1 2026), $11.2 billion (Q4 2025), and $10.6 billion (Q3 2025).